Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus (Albumin Bound) + Octreotide in Metastatic GEP-NETs
NCT07165886Phase 3Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 3, randomised trial in gastroenteropancreatic neuroendocrine tumor (GEP-NET) (3 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Adverse Events up to 3 years, Dose Limiting Toxicity up to 1 year and 3 more. Started Aug 2025; status: recruiting.
02
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT07165886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07165886.